with low vitamin D 3 levels. Weight-bearing was not permitted. Patients were evaluated at intervals of 6 weeks and all investigations were repeated at intervals of 3 months. Student's t-test was used to analyse the data. The study was approved by the Hinduja Hospital ethics committee.
In all, 18 patients with AVN of the hip were seen between February and October 2000. Of these, two were excluded (one because of inability to be followed up, one because of an abnormal renal profile). The aetiology of AVN was steroids in 11, alcohol in three and trauma and idiopathic in one case each. Mean age was 34 yr (range 19-44 yr). There were equal numbers of males and females. In 14 patients, both hips were involved. The mean duration of AVN was 13.8 months (range 1-72 months). The mean period of follow-up on alendronate was 24.76 weeks (range 12-36 weeks).
After 12 weeks of treatment, there was a significant improvement in pain, disability, standing and walking capacity (P < 0.0003), which was still present at 24 weeks (Table 1) . Concomitantly, there was significant improvement in the range of movement at the hip (P < 0.05). The MRI remained stable in 15 of 16 patients (two at stage C and 14 at stage D before treatment; one at stage C and 15 at stage D after treatment), with resolution of oedema in four and of osteoporosis and joint effusion in one patient each. The analgesic requirement declined considerably in all patients, 13 of 16 needing only an occasional analgesic after 6 weeks.
The mechanism of the beneficial action of alendronate in AVN is not clear, and one can only speculate. Bisphosphonates inhibit the resorptive action of mature osteoclasts. Furthermore, they increase the level of apoptosis of osteoclasts in vitro and may decrease apoptosis of osteoblasts and osteocytes [3] . These effects may prevent progressive bone resorption and collapse of the bone. Another beneficial effect seen is a decrease in oedema at the site of AVN. Bisphosphonates have been used in many conditions characterized by abnormal bone formation and remodelling; AVN seems to be one more indication. More studies involving larger numbers, early cases and a longer follow-up period are essential if the role of bisphosphonates in AVN is to be evaluated fully. Correspondence to: S. Agarwala. 
